Online inquiry

IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10550MR)

This product GTTS-WQ10550MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10550MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6616MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ8027MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12734MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ9820MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ13420MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ2288MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ161MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ7421MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW